SC-514

Cat. No.: HY-13802  
CAS No.: 354812-17-2  
Molecular Formula: C₉H₈N₂OS₂  
Molecular Weight: 224.3  
Target: IKK  
Pathway: NF-κB

Storage:
- Powder: -20°C 3 years, 4°C 2 years  
- In solvent: -80°C 6 months, -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro: DMSO : 100 mg/mL (445.83 mM; Need ultrasonic)

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>4.4583 mL</td>
<td>22.2916 mL</td>
<td>44.5831 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.8917 mL</td>
<td>4.4583 mL</td>
<td>8.9166 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.4458 mL</td>
<td>2.2292 mL</td>
<td>4.4583 mL</td>
<td></td>
</tr>
</tbody>
</table>

Preparing Stock Solutions:  
Please refer to the solubility information to select the appropriate solvent.

In Vivo: Add each solvent one by one:  
1. 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ mg/mL; Clear solution  
2. 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ mg/mL; Clear solution  
3. 10% DMSO >> 90% corn oil  
Solubility: ≥ mg/mL; Clear solution

BIOLOGICAL ACTIVITY

Description: SC-514 is a selective IKK-2 inhibitor (IC₅₀=11.2±4.7 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.

<table>
<thead>
<tr>
<th>IC₅₀ &amp; Target</th>
<th>IKK-2</th>
<th>CDK2/A</th>
<th>AUR2</th>
<th>PRAK</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC₅₀</td>
<td>11.2 μM</td>
<td>61 μM</td>
<td>71 μM</td>
<td>75 μM</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
In Vitro
SC-514 inhibits the native IKK complex or recombinant human IKK-1/IKK-2 heterodimer with IC₅₀s of 6.1±2.2 μM and 2.7±0.7 μM, respectively. IKK-2 inhibition by SC-514 is selective, reversible, and competitive with ATP. SC-514 inhibits transcription of NF-κB-dependent genes in IL-1β-induced rheumatoid arthritis-derived synovial fibroblasts in a dose-dependent manner. SC-514 inhibits all forms of recombinant human IKK-2 including rhIKK-2 homodimer, rhIKK-1/rhIKK-2 heterodimer, as well as the constitutively active form of rhIKK-2 with comparable IC₅₀ values in the 3-12 μM range[1]. To evaluate whether the reactive oxygen species (ROS)-inducing IKKβ inhibitor increases the sensitivity of melanoma cells to nitrosourea. The responses of melanoma cells are first assessed to SC-514/Fotemustine co-treatment. Melanoma cell lines are treated with 50 μM of SC-514 and Fotemustine alone and in combination for 48 h and growth inhibition is assessed. Co-treatment with SC-514 significantly enhances Fotemustine-induced cytotoxicity in all melanoma cell lines tested[2].

In Vivo
SC-514 is efficacious in an acute model of inflammation, namely LPS-induced serum TNFα production in the rat. SC-514 shows a dose-dependent inhibition of TNFα production, validating IKK-2 as a potential anti-inflammatory drug target in vivo[1]. To obtain in vivo evidence for the implication of SC-514 in the response of cancer cells to Fotemustine, the xenograft mouse model of melanoma is used. Nude mice engrafted with A375 or G361 tumors are treated with vehicle control and 25 mg/kg SC-514 and/or 25 mg/kg Fotemustine daily for 13-15 consecutive days and the tumor behavior is monitored. Fotemustine treatment with SC-514 shows a clear combined effect and reduces the size of tumors in mice[2].

PROTOCOL

Kinase Assay[1]
IKK complexes are immunoprecipitated from IL-1β-treated RASF cell lysates (0.5-2 mg) using a NEMO antibody (3-10 μg) followed by the addition of protein A-agarose beads. Antibody complexes are pelleted by centrifugation and washed 3 times with 1 mL of cold whole-cell lysis buffer followed by 2 washes in kinase buffer (25 mM HEPES, pH 7.6, 2 mM MgCl₂, 2 mM MnCl₂, 10 mM NaF, 5 mM DTT, and 1 mM phenylmethylsulfonyl fluoride). 100-200 μg of immunoprecipitated IKK is analyzed for kinase activity in a reaction containing 10 μM biotinylated IκBα peptide as substrate and 1 μM [γ-³³P]ATP (2500 Ci/mmol). After incubation at room temperature for 30 min, 25 μL of the reaction mixture is withdrawn and added to a SAM 96 biotin capture plate. After successive wash steps the plate was allowed to air-dry, and 25 μL of scintillation fluid is added to each well. Incorporation of [γ-³³P]ATP is measured using a Top-Count NXT[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay[2]
For crystal violet staining assay, melanoma cell lines (1×10⁴) are seeded in 60 mm dishes, and then untreated or pretreated with SC-514 (50 μM) and/or Fotemustine. Then, cells are formalin-fixed and stained with crystal violet. Cell numbers are measured as the optical density at 595 nm (OD595) of solubilized crystal violet from formalin-fixed cells. Cytotoxicity are also determined by the MTT reduction assay[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration[1][2]
Rats[1]
SC-514 or vehicle (2% Me₂SO in saline) is administered either by oral gavage (50 mg/kg) or intraperitoneally (10 and 50 mg/kg) to adult male Wistar rats that have been deprived of food overnight. Two hours after compound treatment, 1 mg/kg LPS (Escherichia coli) in saline is administered intraperitoneally 90 min after LPS administration; the animals are bled and serum TNFα levels analyzed by a rat-specific TNFα ELISA.
Mice[2]
Male nu/nu BALB/c mice (6 weeks old) are maintained in individual ventilated cages. A375 or G361 (5×10⁶) cells are resuspended in 0.1 mL PBS and inoculated subcutaneously into the backs of nude mice and allowed to grow for 7 days. After that, mice are randomly assigned to 4 groups (n=6 for each group) and treated by intraperitoneal
injection with 200 µL 30% PEG/5% Tween-80 solution as the vehicle control and 25 mg/kg SC-514 and/or 25 mg/kg Fotemustine daily for 13-15 consecutive days. Body weight and tumor volume are measured every 3 days. Tumor volumes are determined by a caliper and calculated. At the end of the experiment, mice are sacrificed and tumor xenografts are collected. Tumor tissues are stored at -80°C for Western blot analysis.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Bone Miner Res. 2019 May 20.

See more customer validations on www.MedChemExpress.com

REFERENCES
